Net Loss Per Share

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Net Loss Per Share

10. Net Loss Per Share

Basic and diluted net loss per common share is calculated by dividing net loss applicable to Heat Biologics, Inc. by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company’s potentially dilutive shares, which include outstanding stock options and warrants, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. The following table reconciles net loss to net loss attributable to Heat Biologics, Inc.:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Net loss	$	(2,504,178	)	$	(1,663,988	)	$	(9,053,987	)	$	(9,431,241	)
Net loss: Non-controlling interest		(203,371	)		(47,042	)		(344,328	)		(329,471	)
Net loss attributable to Heat Biologics, Inc.	$	(2,300,807	)	$	(1,616,946	)	$	(8,709,659	)	$	(9,101,770	)
Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.—basic and diluted		35,786,606			19,420,026			32,695,360			15,371,267
Net loss per share attributable to Heat Biologics, Inc.—basic and diluted	$	(0.06	)	$	(0.08	)	$	(0.27	)	$	(0.59	)

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:

	For the Nine Months Ended September 30,
	2017		2016
Outstanding stock options		2,673,549		1,219,847
Outstanding restricted stock units		291,375		—
Outstanding common stock warrants		3,103,963		4,193,410